<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04310241</url>
  </required_header>
  <id_info>
    <org_study_id>12-915</org_study_id>
    <nct_id>NCT04310241</nct_id>
  </id_info>
  <brief_title>Visual Function Abnormalities in Strabismus and Amblyopia and Response to Therapy</brief_title>
  <official_title>Oculomotor Disorders: Experimental and Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amblyopia and strabismus are characterized by a reduction in visual acuity, contrast
      sensitivity, grating acuity, vernier acuity, reading difficulties and binocular visual
      function deficits. Treated patients have residual visual function deficits. The purpose of
      the current study is to quantify various visual functions in amblyopic and strabismic
      participants at baseline, during and at the completion of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To examine the response of therapy on visual functions in amblyopic and strabismic
      participants.

      The following visual functions will be measured prior to treatment. Eye movements, contrast
      sensitivity, grating acuity, visual acuity, vernier acuity, binocular visual functions,
      reading and visual scanning will be measured. The testing will comprise of one or more of the
      above paradigms depending on participant's cooperation and understanding as majority of the
      study participants will be children. The above measurements will be repeated during amblyopia
      therapy ( which comprises of glasses, patching and/or atropine eye drops) and at the
      completion of treatment. For participants with strabismus requiring strabismus surgery the
      measurements will be repeated after strabismus surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2020</start_date>
  <completion_date type="Anticipated">March 12, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 12, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Functions</measure>
    <time_frame>0-3 years depending on duration of treatment</time_frame>
    <description>contrast sensitivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Functions</measure>
    <time_frame>0-3 years depending on duration of treatment</time_frame>
    <description>visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual functions</measure>
    <time_frame>0-3 years depending on duration of treatment</time_frame>
    <description>vernier acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual functions</measure>
    <time_frame>0-3 years depending on duration of treatment</time_frame>
    <description>grating acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual functions</measure>
    <time_frame>0-3 years depending on duration of treatment</time_frame>
    <description>binocular functions- stereopsis, inter-ocular functions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual functions</measure>
    <time_frame>0-3 years depending on duration of treatment</time_frame>
    <description>eye movement measurements</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual functions</measure>
    <time_frame>0-3 years depending on duration of treatment</time_frame>
    <description>reading- reading speeds, eye movement measurements</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Amblyopia</condition>
  <condition>Strabismus</condition>
  <arm_group>
    <arm_group_label>Control subjects</arm_group_label>
    <description>Subjects who state they have no eye or neurologic problems or disease other than perhaps wearing glasses or contact lenses and upon review of medical history.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amblyopia</arm_group_label>
    <description>Clinical diagnosis of amblyopia</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Patching therapy, Glasses</intervention_name>
    <description>Patching, glasses and strabismus surgery are commonly employed measures in treatment of amblyopia and strabismus.</description>
    <arm_group_label>Amblyopia</arm_group_label>
    <other_name>Strabismus surgery</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        children with diagnosis of strabismus and/or amblyopia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of amblyopia or presence of amblyogenic risk factors.

        Exclusion Criteria:

          -  History of neurologic disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Fatema Ghasia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kimberly Baynes, MSN</last_name>
    <phone>216-444-2566</phone>
    <email>baynesk@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatema Ghasia, MD</last_name>
      <phone>216-318-7809</phone>
    </contact>
    <contact_backup>
      <last_name>Kimberly Baynes</last_name>
      <phone>2164442566</phone>
      <email>baynesk@ccf.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chatzistefanou KI, Theodossiadis GP, Damanakis AG, Ladas ID, Moschos MN, Chimonidou E. Contrast sensitivity in amblyopia: the fellow eye of untreated and successfully treated amblyopes. J AAPOS. 2005 Oct;9(5):468-74.</citation>
    <PMID>16213398</PMID>
  </reference>
  <results_reference>
    <citation>Shaikh AG, Otero-Millan J, Kumar P, Ghasia FF. Abnormal Fixational Eye Movements in Amblyopia. PLoS One. 2016 Mar 1;11(3):e0149953. doi: 10.1371/journal.pone.0149953. eCollection 2016.</citation>
    <PMID>26930079</PMID>
  </results_reference>
  <results_reference>
    <citation>Ghasia FF, Otero-Millan J, Shaikh AG. Abnormal fixational eye movements in strabismus. Br J Ophthalmol. 2018 Feb;102(2):253-259. doi: 10.1136/bjophthalmol-2017-310346. Epub 2017 Jul 11.</citation>
    <PMID>28698242</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Fatema Ghasia</investigator_full_name>
    <investigator_title>Associate Staff</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amblyopia</mesh_term>
    <mesh_term>Strabismus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Research publications require inclusion of de-identified data in the manuscript. We will also be presenting the data at local, national and international conferences.</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>starting 6 months after publication</ipd_time_frame>
    <ipd_access_criteria>The de-identified research data will be shared with colleagues and will be published after peer-review.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

